GlassScriptPhysician profile
Sandeep Kalra
NPI 1376622092
$1,389.04
in general payments reported to CMS, 2019-2025
29 companies · $46.56 in 2025
The $46.56 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $692 · 2020: $211 · 2021: $161 · 2022: $137 · 2023: $125 · 2024: $16.50 · 2025: $46.56.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $188.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $282.84 | 2019-2022 | |
| Abbvie INC. | $133.34 | 2019-2023 | |
| Amgen INC. | $124.37 | 2019-2023 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $91.70 | 2019-2021 | |
| Corcept Therapeutics | $85.07 | 2019-2022 | |
| Abbott Laboratories | $83.35 | 2023 | Proclaim, Infinity |
| Novo Nordisk INC | $78.81 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $53.38 | 2019-2020 | |
| Ascensia Diabetes Care US INC. | $41.43 | 2024-2025 | |
| Lilly USA, LLC | $38.06 | 2019 | |
| Masimo Corporation | $35.23 | 2019 | |
| Amarin Pharma, INC. | $31.59 | 2019-2020 | |
| Boston Scientific Corporation | $26.52 | 2019 | |
| Kyowa Kirin, INC. | $23.78 | 2019 | |
| Beta Bionics, INC. | $21.63 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $21.48 | 2022 | |
| Shire North American Group INC | $20.90 | 2019 | |
| Neurocrine Biosciences, INC. | $20.49 | 2022 | |
| Shionogi INC | $20.35 | 2019 | |
| Merck Sharp & Dohme LLC | $19.32 | 2019 | |
| Hikma Pharmaceuticals USA | $18.12 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.15 | 2021 | |
| Sanofi Pasteur INC. | $16.82 | 2019 | |
| Adlon Therapeutics L.P. | $16.11 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.83 | 2019 | |
| Glaxosmithkline, LLC. | $13.92 | 2019 | |
| Pfizer INC. | $13.71 | 2022 | |
| Medtronic USA, INC. | $12.41 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandeep Kalra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.